4
Changes in Ownership
ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001209191-20-062797
Chief Executive Officer sold 55,000 shares at an average $68.73 ($3,780,347)
- Chief Executive Officer acquired 55,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard Chief Executive Officer | 2020-12-08 | Option exercise | +16,324 | $2.01 | $32,811 | 2,521,561 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2020-12-08 | Sale | −16,324 | $67.97 | $1,109,542 | 2,505,237 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2020-12-09 | Option exercise | +38,676 | $2.01 | $77,739 | 2,543,913 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2020-12-09 | Sale | −16,726 | $67.27 | $1,125,158 | 2,527,187 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2020-12-09 | Sale | −12,067 | $69.80 | $842,277 | 2,515,120 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2020-12-09 | Sale | −5,880 | $70.87 | $416,716 | 2,509,240 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2020-12-09 | Sale | −4,003 | $71.61 | $286,655 | 2,505,237 | D |
| Derivatives | |||||||
| Anzalone Christopher Richard Chief Executive Officer | 2020-12-08 | Option exercise · Stock Option (right to buy) | −16,324 | 879,219 | D | ||
| Anzalone Christopher Richard Chief Executive Officer | 2020-12-09 | Option exercise · Stock Option (right to buy) | −38,676 | 840,543 | D | ||
| Open-market sales · 55,000 sh · avg $68.73 · $3,780,347 | |||||||
Loading xslF345X03/doc4.xml…